Mira Pharmaceuticals' MIRA-55 Demonstrates Superior Efficacy Over THC In Preclinical Studies
MIRA Pharmaceuticals unveils potent anxiety treatment, MIRA-55, outperforming THC in preclinical studies.
Breaking News
Jul 16, 2024
Mrudula Kulkarni

MIRA Pharmaceuticals, Inc., a company in the early stages of
pharmaceutical development, has revealed encouraging results from its recent
preclinical studies on MIRA-55, an innovative oral pharmaceutical marijuana
analog. MIRA-55 is being explored as a potential treatment for anxiety and
cognitive decline. The latest findings validate MIRA's previous expectations
about MIRA-55's pharmacological characteristics and its potential
effectiveness. Notably, these preclinical results compared MIRA-55 directly with
THC, marijuana's primary psychoactive ingredient, and yielded promising
outcomes.
Initially, MIRA centered its marijuana analog preclinical
research program on an oral compound named "MIRA1a." In late 2023,
following conversations with contract manufacturers, MIRA began to suspect that
MIRA1a was actually a novel molecule with a unique chemical structure, which
they subsequently named "MIRA-55." This revelation prompted MIRA to
file a global provisional patent application for MIRA-55 in March 2024. At that
time, MIRA expressed its belief that MIRA-55 exhibited greater potency and
potential efficacy compared to MIRA1a, although further testing was needed to
substantiate these preliminary findings. The new test results released today
confirm MIRA's initial assessments.
The latest preclinical research, carried out both in vitro
and using a mouse model, validates that MIRA-55 presents significant advantages
over THC. MIRA-55 exhibited greater efficacy at the CB1 and CB2 cannabinoid
receptors compared to THC, with a more pronounced and sustained increase in
agonist activity as concentration levels rose. This suggests that MIRA-55 could
be more effective in activating key cannabinoid receptors responsible for its
therapeutic effects. These findings support MIRA's belief that MIRA-55 could
offer stronger and more reliable relief for conditions like anxiety and
cognitive decline.
Moreover, MIRA-55 seems to maintain a unique balance between
its activity on the CB1 and CB2 receptors, potentially supporting its
effectiveness across a wider range of doses. Unlike THC, which tends to lose
efficacy at higher doses, MIRA-55 demonstrated robust efficacy even as doses
increased. This sustained activity implies that MIRA-55 could provide more
consistent and prolonged therapeutic benefits, making it a more promising
candidate for its intended uses.
In studies examining its potential to alleviate anxiety,
MIRA-55 consistently showed dose-dependent reductions in anxiety-like
behaviors. In the Open Field Test and Elevated Plus Maze Test, MIRA-55
demonstrated a more predictable and stronger anxiolytic effect than THC.
Testing subjects spent more time in the center of the field and the open arms
of the maze, indicating reduced anxiety levels. While THC was effective, its
results were more variable and less consistent compared to MIRA-55.